The Netherlands is experiencing a significant rise in hepatocellular carcinoma (HCC), the most common form of primary liver cancer. A nationwide analysis of cancer registry data from 2014 to 2022 found the overall HCC incidence rate increased at an average annual pace of 2.3%.
The most striking trend emerged in cases linked to metabolic dysfunction-associated steatotic liver disease (MASLD). HCC associated with this metabolic condition showed the fastest growth, with an average annual increase of 8.3%. While alcohol-related liver disease remains the leading underlying cause overall, this shift signals a major change in liver disease patterns.
Despite advancements in treatment, survival outcomes for HCC patients remain poor. The five-year survival rate stood at just 18.8%. Researchers found that receiving curative-intent treatment was the strongest predictor of better survival. However, disease severity, including distant metastases and advanced liver failure (Child-Pugh C), predicted higher mortality.
A key challenge highlighted by the study is that approximately 40% of MASLD-related HCC cases develop without cirrhosis. This can potentially limit the effectiveness of current surveillance programs designed to detect cancer in high-risk cirrhotic patients. The findings underscore an urgent need for increased clinical awareness and updated screening strategies to enable earlier detection.